Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.82 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL1092313 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL30516198 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL9342231 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL19704479 | 0.95 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL30114591 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL28275189 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL27567468 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL615 | 0.91 | — | — | |
| Maleic Acid SCHEMBL2046430 | 0.91 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL3998225 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126637-A1 | COMPOSITIONS CONTAINING FEXOFENADINE | OPELLA HEALTHCARE GROUP SAS (FR) | 2023-07-06 | — | — | WO | claimed |
| WO-2019020777-A1 | LIQUID FORMULATION OF A VEGF ANTAGONIST | FORMYCON AG (DE) | 2019-01-31 | — | — | WO | claimed |
| CN-112851796-B | Collagen conjugated enone derivative and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023126637-A1 | COMPOSITIONS CONTAINING FEXOFENADINE | OPELLA HEALTHCARE GROUP SAS (FR) | 2023-07-06 | — | — | WO | disclosed |
| CN-112851796-A | Collagen conjugated ketene derivative and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2021-05-28 | — | — | CN | disclosed |
| CN-109331847-A | A kind of catalysis oxidation furfural prepares catalyst and its application of maleic acid | 合肥能源研究院 | 2019-02-15 | — | — | CN | disclosed |
| WO-2019020777-A1 | LIQUID FORMULATION OF A VEGF ANTAGONIST | FORMYCON AG (DE) | 2019-01-31 | — | — | WO | disclosed |
| US-8933097-B2 | Fexofenadine suspension formulation | SANOFI-AVENTIS U.S. LLC (US) | 2015-01-13 | — | — | US | disclosed |
| CN-101316580-B | Fexofenadine suspension formulation | SANOFI AVENTIS US LLC | 2011-11-16 | — | — | CN | disclosed |
| EP-1965768-B1 | FEXOFENADINE SUSPENSION FORMULATION | SANOFI AVENTIS US LLC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080299211-A1 | FEXOFENADINE SUSPENSION FORMULATION | SANOFI-AVENTIS U.S. LLC. (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1690519-A1 | ALPHA-GLUCOSIDASE ACTIVITY INHIBITOR | Meiji Dairies Corporation (JP) | 2006-08-16 | — | — | EP | disclosed |
| EP-0331327-B1 | Agent for blocking nonspecific adsorption, process for preparing thereof and method of blocking nonspecific adsorption | SNOW BRAND MILK PRODUCTS CO LTD (JP) | 1994-07-20 | — | — | EP | disclosed |
| US-5017559-A | Milk protein, organic acid or salt | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0331327-A2 | Agent for blocking nonspecific adsorption, process for preparing thereof and method of blocking nonspecific adsorption | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| EP-0176190-B1 | METHOD OF FRACTURING SUBTERRANEAN FORMATIONS | HALLIBURTON COMPANY (US) | 1989-06-07 | — | — | EP | disclosed |
| EP-0176940-A2 | Polysaccharides, methods for preparing such polysaccharides and fluids utilizing such polysaccharides | UNION CARBIDE CORPORATION (US) | 1986-04-09 | — | — | EP | disclosed |
| EP-0176190-A2 | Method of fracturing subterranean formations | HALLIBURTON COMPANY (US) | 1986-04-02 | — | — | EP | disclosed |
| US-4579942-A | WATER-SOLUBLE CELLULOSE ETHERS HAVING GOOG SHEAR-THERMAL STABILITYCHARACTERISTICS | UNION CARBIDE CORPORATION (US) | 1986-04-01 | — | — | US | disclosed |
| US-4553601-A | Method for fracturing subterranean formations | HALLIBURTON COMPANY (US) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299211-A1 | FEXOFENADINE SUSPENSION FORMULATION | PEF1, SLC10A2, FLAD1 | TSHR 2382/4885TP53 4559/4885EGLN1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.